
Sanofi ADR is a drug manufacturers-general business based in the US. Sanofi ADR shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Sanofi ADR employs 95,442 staff and has a trailing 12-month revenue of around $44.3 billion.
How to buy Sanofi ADR stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – SNY. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Sanofi ADR stock price (NASDAQ: SNY)
Use our graph to track the performance of SNY stocks over time.Sanofi ADR shares at a glance
Latest market close | $48.49 |
---|---|
52-week range | $36.91 - $56.08 |
50-day moving average | $46.98 |
200-day moving average | $47.15 |
Wall St. target price | $64.00 |
PE ratio | 17.6679 |
Dividend yield | $3.33 (3.59%) |
Earnings per share (TTM) | $2.77 |
Buy Sanofi ADR stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Sanofi ADR stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sanofi ADR price performance over time
Historical closes compared with the close of $48.49 from 2023-01-27
1 week (2023-01-23) | -0.29% |
---|---|
1 month (2022-12-30) | 0.12% |
3 months (2022-10-31) | 12.17% |
6 months (2022-07-29) | -2.43% |
1 year (2022-01-31) | -6.75% |
---|---|
2 years (2021-01-29) | 2.71% |
3 years (2020-01-31) | 0.46% |
5 years (2018-01-30) | 8.21% |
Is Sanofi ADR stock undervalued or overvalued?
Valuing Sanofi ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sanofi ADR's P/E ratio
Sanofi ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Sanofi ADR shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sanofi ADR's PEG ratio
Sanofi ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6501. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sanofi ADR's EBITDA
Sanofi ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.2 billion.
The EBITDA is a measure of a Sanofi ADR's overall financial performance and is widely used to measure a its profitability.
Sanofi ADR financials
Revenue TTM | $44.3 billion |
---|---|
Operating margin TTM | 23.98% |
Gross profit TTM | $26.9 billion |
Return on assets TTM | 4.91% |
Return on equity TTM | 10% |
Profit margin | 14.45% |
Book value | $28.34 |
Market capitalisation | $123.9 billion |
TTM: trailing 12 months
Sanofi ADR share dividends
Dividend payout ratio: 48.2% of net profits
Recently Sanofi ADR has paid out, on average, around 48.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.59% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi ADR shareholders could enjoy a 3.59% return on their shares, in the form of dividend payments. In Sanofi ADR's case, that would currently equate to about $3.33 per share.
While Sanofi ADR's payout ratio might seem fairly standard, it's worth remembering that Sanofi ADR may be investing much of the rest of its net profits in future growth.
Sanofi ADR's most recent dividend payout was on 26 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 25 May 2022 (the "ex-dividend date").
Have Sanofi ADR's shares ever split?
Sanofi ADR's shares were split on a 5:1 basis on 29 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi ADR shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi ADR shares which in turn could have impacted Sanofi ADR's share price.
Sanofi ADR share price volatility
Over the last 12 months, Sanofi ADR's shares have ranged in value from as little as $36.91 up to $56.0802. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi ADR's is 0.4349. This would suggest that Sanofi ADR's shares are less volatile than average (for this exchange).
Sanofi ADR overview
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange.
Sanofi ADR in the news

UPDATE 1-Drugmakers prevail in dispute over U.S. discount drug program
U.S. Appeals Court Sides With Drugmakers on Discount Program
Drugmakers prevail in dispute over U.S. discount drug program
Frequently asked questions
What percentage of Sanofi ADR is owned by insiders or institutions?Currently 0.006% of Sanofi ADR shares are held by insiders and 10.286% by institutions. How many people work for Sanofi ADR?
Latest data suggests 95,442 work at Sanofi ADR. When does the fiscal year end for Sanofi ADR?
Sanofi ADR's fiscal year ends in December. Where is Sanofi ADR based?
Sanofi ADR's address is: 54, Rue La BoEtie, Paris, France, 75008 What is Sanofi ADR's ISIN number?
Sanofi ADR's international securities identification number is: US80105N1054 What is Sanofi ADR's CUSIP number?
Sanofi ADR's Committee on Uniform Securities Identification Procedures number is: 80105N204
More guides on Finder
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert